MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma

Giorgio Malpeli, Stefano Barbi, Corinna Greco, Simonetta Zupo, Anna Bertolaso, Maria Teresa Scupoli, Mauro Krampera, Paul Takam Kamga, Carlo Maria Croce, Aldo Scarpa, Alberto Zamò

Research output: Contribution to journalArticle

Abstract

First line drug treatment of follicular lymphoma (FL) patients is followed by a highly variable disease-free time before relapse in about one third of patients. No molecular marker is able to predict efficiently the risk of relapse. We investigated the expression profile of microRNAs (miRNAs) by microarrays and of the tumor microenvironment by immunohistochemistry in 26 FLs and 12 reactive lymph nodes (rLN) as reference. Twenty-nine miRNAs were differentially expressed in FLs compared to rLNs and some of them discriminated grade 1 from 3a FLs. Both FLs and rLNs displayed molecular heterogeneity. FLs grouped into two clusters mostly driven by the tumor T-cell content. Among 21 drug-treated FL patients with an average followup of 13.5 years, eight cases relapsed. Twenty-six miRNAs discriminated between relapsed and non-relapsed FLs. Ten miRNAs also correlated with Foxp3+ cells number. Notably, Foxp3+ cells were significantly less in relapsed patients and lower Foxp3+ cell number associated with shorter time-to-relapse. Foxp3+ cells did not co-expressed follicular helper T-cell markers and were therefore classified as regulatory T cells rather than follicular regulatory T-cells. These findings introduce new knowledge about the relationship between miRNA alterations and infiltrating immune cells and show that Foxp3+ cells might be predictive of disease relapse.

Original languageEnglish
Pages (from-to)19961-19979
Number of pages19
JournalOncotarget
Volume9
Issue number28
DOIs
Publication statusPublished - Apr 13 2018

Fingerprint

Follicular Lymphoma
MicroRNAs
Cell Count
Recurrence
Regulatory T-Lymphocytes
Tumor Microenvironment
Helper-Inducer T-Lymphocytes
Pharmaceutical Preparations
Lymph Nodes
Immunohistochemistry
T-Lymphocytes
Neoplasms

Keywords

  • Follicular lymphoma
  • Foxp3
  • Heterogeneity
  • MicroRNAs
  • Relapse

ASJC Scopus subject areas

  • Oncology

Cite this

Malpeli, G., Barbi, S., Greco, C., Zupo, S., Bertolaso, A., Scupoli, M. T., ... Zamò, A. (2018). MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. Oncotarget, 9(28), 19961-19979. https://doi.org/10.18632/oncotarget.24987

MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. / Malpeli, Giorgio; Barbi, Stefano; Greco, Corinna; Zupo, Simonetta; Bertolaso, Anna; Scupoli, Maria Teresa; Krampera, Mauro; Kamga, Paul Takam; Croce, Carlo Maria; Scarpa, Aldo; Zamò, Alberto.

In: Oncotarget, Vol. 9, No. 28, 13.04.2018, p. 19961-19979.

Research output: Contribution to journalArticle

Malpeli, G, Barbi, S, Greco, C, Zupo, S, Bertolaso, A, Scupoli, MT, Krampera, M, Kamga, PT, Croce, CM, Scarpa, A & Zamò, A 2018, 'MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma', Oncotarget, vol. 9, no. 28, pp. 19961-19979. https://doi.org/10.18632/oncotarget.24987
Malpeli, Giorgio ; Barbi, Stefano ; Greco, Corinna ; Zupo, Simonetta ; Bertolaso, Anna ; Scupoli, Maria Teresa ; Krampera, Mauro ; Kamga, Paul Takam ; Croce, Carlo Maria ; Scarpa, Aldo ; Zamò, Alberto. / MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. In: Oncotarget. 2018 ; Vol. 9, No. 28. pp. 19961-19979.
@article{dd1504b817e74205911f20f21f901f42,
title = "MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma",
abstract = "First line drug treatment of follicular lymphoma (FL) patients is followed by a highly variable disease-free time before relapse in about one third of patients. No molecular marker is able to predict efficiently the risk of relapse. We investigated the expression profile of microRNAs (miRNAs) by microarrays and of the tumor microenvironment by immunohistochemistry in 26 FLs and 12 reactive lymph nodes (rLN) as reference. Twenty-nine miRNAs were differentially expressed in FLs compared to rLNs and some of them discriminated grade 1 from 3a FLs. Both FLs and rLNs displayed molecular heterogeneity. FLs grouped into two clusters mostly driven by the tumor T-cell content. Among 21 drug-treated FL patients with an average followup of 13.5 years, eight cases relapsed. Twenty-six miRNAs discriminated between relapsed and non-relapsed FLs. Ten miRNAs also correlated with Foxp3+ cells number. Notably, Foxp3+ cells were significantly less in relapsed patients and lower Foxp3+ cell number associated with shorter time-to-relapse. Foxp3+ cells did not co-expressed follicular helper T-cell markers and were therefore classified as regulatory T cells rather than follicular regulatory T-cells. These findings introduce new knowledge about the relationship between miRNA alterations and infiltrating immune cells and show that Foxp3+ cells might be predictive of disease relapse.",
keywords = "Follicular lymphoma, Foxp3, Heterogeneity, MicroRNAs, Relapse",
author = "Giorgio Malpeli and Stefano Barbi and Corinna Greco and Simonetta Zupo and Anna Bertolaso and Scupoli, {Maria Teresa} and Mauro Krampera and Kamga, {Paul Takam} and Croce, {Carlo Maria} and Aldo Scarpa and Alberto Zam{\`o}",
year = "2018",
month = "4",
day = "13",
doi = "10.18632/oncotarget.24987",
language = "English",
volume = "9",
pages = "19961--19979",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "28",

}

TY - JOUR

T1 - MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma

AU - Malpeli, Giorgio

AU - Barbi, Stefano

AU - Greco, Corinna

AU - Zupo, Simonetta

AU - Bertolaso, Anna

AU - Scupoli, Maria Teresa

AU - Krampera, Mauro

AU - Kamga, Paul Takam

AU - Croce, Carlo Maria

AU - Scarpa, Aldo

AU - Zamò, Alberto

PY - 2018/4/13

Y1 - 2018/4/13

N2 - First line drug treatment of follicular lymphoma (FL) patients is followed by a highly variable disease-free time before relapse in about one third of patients. No molecular marker is able to predict efficiently the risk of relapse. We investigated the expression profile of microRNAs (miRNAs) by microarrays and of the tumor microenvironment by immunohistochemistry in 26 FLs and 12 reactive lymph nodes (rLN) as reference. Twenty-nine miRNAs were differentially expressed in FLs compared to rLNs and some of them discriminated grade 1 from 3a FLs. Both FLs and rLNs displayed molecular heterogeneity. FLs grouped into two clusters mostly driven by the tumor T-cell content. Among 21 drug-treated FL patients with an average followup of 13.5 years, eight cases relapsed. Twenty-six miRNAs discriminated between relapsed and non-relapsed FLs. Ten miRNAs also correlated with Foxp3+ cells number. Notably, Foxp3+ cells were significantly less in relapsed patients and lower Foxp3+ cell number associated with shorter time-to-relapse. Foxp3+ cells did not co-expressed follicular helper T-cell markers and were therefore classified as regulatory T cells rather than follicular regulatory T-cells. These findings introduce new knowledge about the relationship between miRNA alterations and infiltrating immune cells and show that Foxp3+ cells might be predictive of disease relapse.

AB - First line drug treatment of follicular lymphoma (FL) patients is followed by a highly variable disease-free time before relapse in about one third of patients. No molecular marker is able to predict efficiently the risk of relapse. We investigated the expression profile of microRNAs (miRNAs) by microarrays and of the tumor microenvironment by immunohistochemistry in 26 FLs and 12 reactive lymph nodes (rLN) as reference. Twenty-nine miRNAs were differentially expressed in FLs compared to rLNs and some of them discriminated grade 1 from 3a FLs. Both FLs and rLNs displayed molecular heterogeneity. FLs grouped into two clusters mostly driven by the tumor T-cell content. Among 21 drug-treated FL patients with an average followup of 13.5 years, eight cases relapsed. Twenty-six miRNAs discriminated between relapsed and non-relapsed FLs. Ten miRNAs also correlated with Foxp3+ cells number. Notably, Foxp3+ cells were significantly less in relapsed patients and lower Foxp3+ cell number associated with shorter time-to-relapse. Foxp3+ cells did not co-expressed follicular helper T-cell markers and were therefore classified as regulatory T cells rather than follicular regulatory T-cells. These findings introduce new knowledge about the relationship between miRNA alterations and infiltrating immune cells and show that Foxp3+ cells might be predictive of disease relapse.

KW - Follicular lymphoma

KW - Foxp3

KW - Heterogeneity

KW - MicroRNAs

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=85045348528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045348528&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24987

DO - 10.18632/oncotarget.24987

M3 - Article

AN - SCOPUS:85045348528

VL - 9

SP - 19961

EP - 19979

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 28

ER -